Treatment Advances and Management of ES-SCLC
Panelists discuss the current treatment landscape of ES-SCLC, review recent clinical trials, and how they prepare their sites for tarlatamab administration, patient monitoring and management of adverse events
| Watch Now |
Featured Video
 |
Institutional Implementation: Setting Up Tarlatamab Administration
Panelists discuss how the administration of tarlatamab requires thorough pretreatment screening, staff training, and close monitoring for immune-related adverse effects such as cytokine release syndrome, emphasizing the importance of patient education, rapid intervention, and specialized infrastructure for safe and effective treatment.
|